{
    "paper_id": "139b9a993204af8852fbdb685a455ee770eb481a",
    "metadata": {
        "title": "Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial",
        "authors": [
            {
                "first": "Chang",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Jianying",
                "middle": [],
                "last": "Huang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Zhenshun",
                "middle": [],
                "last": "Cheng",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Jianyuan",
                "middle": [],
                "last": "Wu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Song",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Yongxi",
                "middle": [],
                "last": "Zhang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Bo",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Mengxin",
                "middle": [],
                "last": "Lu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Yongwen",
                "middle": [],
                "last": "Luo",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Jingyi",
                "middle": [],
                "last": "Zhang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "The Third People's Hospital of Hubei Province",
                    "location": {
                        "postCode": "430033",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Ping",
                "middle": [],
                "last": "Yin",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Huazhong University of Science and Technology",
                    "location": {
                        "postCode": "430030",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Xinghuan",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhongnan Hospital of Wuhan University",
                    "location": {
                        "postCode": "430071",
                        "settlement": "Wuhan",
                        "region": "Hubei",
                        "country": "China"
                    }
                },
                "email": "wangxinghuan@whu.edu.cn"
            }
        ]
    },
    "abstract": [
        {
            "text": "Manuscript word count: Key points 63; Abstract 349; Full text 2924 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Beginning from Dec. 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, followed has spread rapidly throughout China. As of Mar. 14, 600mg/time from the second day to the end of the experiment, twice a day). The control group (arbidol) was treated with routine therapy + arbidol (200 mg each time, 3 times a day, from the first day to the end of the trial). The course of treatment in both groups was 7-10 days. If necessary, the treatment time could be extended to 10 days according to the judgment of researchers. Except arbidol and famiravir, some other drugs were used for conventional therapy and symptomatic treatment to improve adverse reactions. The details of drugs use were listed in Supplementary   Table S1 .",
            "cite_spans": [
                {
                    "start": 326,
                    "end": 327,
                    "text": "3",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [
                {
                    "start": 722,
                    "end": 746,
                    "text": "Supplementary   Table S1",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "Introduction"
        },
        {
            "text": "The primary outcome was the clinical recovery rate at 7 days or the end of treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "Results were stratified for moderate patients with COVID-19, severe patients with COVID-19, COVID-19 patients with hypertension and/or diabetes. Clinical recovery was defined as continuous (>72 hours) recovery of body temperature, respiratory rate, oxygen saturation and cough relief after treatment. It needs to meet several conditions: axillary temperature\u226436.6\u00b0C; respiratory frequency\u226424 times/min; Oxygen saturation\u226598% without oxygen inhalation; mild or no cough. The armpit temperature, respiratory rate, oxygen saturation without oxygen, oxygen therapy and noninvasive positive pressure ventilation (NPPV) were recorded in daily follow-up. Repeated measurements were made at least twice in each follow-up. The measurements were taken after 15 minutes rest at room temperature (23\u00b12\u00b0C).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "Secondary outcomes included the time from randomization to fever reduction (patients with fever at the time of enrollment), the time from randomization to cough All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 88,
                    "end": 96,
                    "text": "Table 2)",
                    "ref_id": "TABREF3"
                }
            ],
            "section": "Definitions"
        },
        {
            "text": "Comparison of duration of fever, cough relief time and auxiliary oxygen therapy or noninvasive mechanical ventilation rate Table 3 displayed duration of fever, cough relief time and auxiliary oxygen therapy or noninvasive mechanical ventilation rate between the favipiravir and arbidol groups.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 123,
                    "end": 130,
                    "text": "Table 3",
                    "ref_id": "TABREF4"
                }
            ],
            "section": "Definitions"
        },
        {
            "text": "For 98 moderate patients in the favipiravir group, 57 had a fever and 60 had a cough;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "for 111 moderate patients in the arbidol group, 65 had a fever and 64 had a cough. For moderate patients, the time of fever reduction and cough relief in the favipiravir group was significantly shorter than that in the arbidol group (P<0.0001).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "For 42 patients with hypertension and/or diabetes in the favipiravir group, 28 had a fever and 25 had a cough; of 35 patients with hypertension and/or diabetes in the All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint arbidol group, 24 had a fever and 23 had a cough. For patients with hypertension and/or diabetes, the time of fever reduction and cough relief in the favipiravir group was also significantly shorter than that in the arbidol group (P<0.0001). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions"
        },
        {
            "text": "During this trial, we detected some antiviral-associated adverse effects. 37 adverse effects cases in the favipiravir group and 28 cases in the arbidol group were observed. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comparison of antiviral-associated adverse effects"
        },
        {
            "text": "The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint 1 9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comparison of antiviral-associated adverse effects"
        },
        {
            "text": "In moderate COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment because of the higher clinical recovery rate of day 7 and more effectively reduced incidence of fever, cough except manageable antiviral-associated adverse effects.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "COVID-19) Situation Report. World Health Organization",
            "authors": [],
            "year": null,
            "venue": "Coronavirus disease 2019",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Coronavirus Disease (COVID-19)-Statistics and Research",
            "authors": [
                {
                    "first": "Max",
                    "middle": [],
                    "last": "Roser",
                    "suffix": ""
                },
                {
                    "first": "Hannah",
                    "middle": [],
                    "last": "Ritchie",
                    "suffix": ""
                },
                {
                    "first": "Esteban",
                    "middle": [],
                    "last": "Ortiz-Ospina",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.1585"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "",
            "issn": "",
            "pages": "30566--30569",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. published online Mar 11",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "30566--30569",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "E"
                    ],
                    "last": "Hulseberg",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "F\u00e9n\u00e9ant",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Szyma\u0144ska-De Wijs",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Virol",
            "volume": "93",
            "issn": "8",
            "pages": "2185--2203",
            "other_ids": {
                "DOI": [
                    "10.1128/JVI.02185-18"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "The mechanism of resistance to favipiravir in influenza",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "H"
                    ],
                    "last": "Goldhill",
                    "suffix": ""
                },
                {
                    "first": "Te",
                    "middle": [],
                    "last": "Velthuis",
                    "suffix": ""
                },
                {
                    "first": "Ajw",
                    "middle": [],
                    "last": "Fletcher",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Proc Natl Acad Sci USA",
            "volume": "115",
            "issn": "45",
            "pages": "11613--11618",
            "other_ids": {
                "DOI": [
                    "10.1073/pnas.1811345115"
                ]
            }
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Chinese diagnosis and treatment plan of COVID-19 patients (The sixth edition)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "For moderate patients, auxiliary oxygen therapy or noninvasive mechanical ventilation rate was 17.12% (19/111) in the arbidol group and 8.16%(8/98)  in the favipiravir group (P=0.0541), with the difference of recovery rate between 2 groups (95% CI) was -0.0895 (-0.1781, -0.0009); for severe patients, auxiliary oxygen therapy or noninvasive mechanical ventilation rate was 88.89 (8/9) in the arbidol group and 72.22% (13/18) in the favipiravir group (P=0.3261), with the difference of recovery rate between 2 groups (95% CI) was -0.1667 (-0.4582, 0.1248); for patients with hypertension and/or diabetes, auxiliary oxygen therapy or noninvasive mechanical ventilation rate was 28.57% (10/35) in the arbidol group and 21.43% (9/42) in the favipiravir group (P=0.4691), with the difference of recovery rate between two groups (95% CI) was -0.0714 (-0.2658, 0.1230). No statistical difference was observed of auxiliary oxygen therapy or noninvasive mechanical ventilation rate between 2 groups (both P>0.05). For all cases enrolled in this study, the all-cause mortality was 0. The rate of new dyspnea in arbidol group was 11.67% (14/120) and in favipiravir group was 3.45% (4/116) with P=0.0174. The cases of respiratory failure in the two group were both 4.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure legend",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Flow Diagram of the Study.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "relief (patients with moderate or severe cough at the time of enrollment), the rate of auxiliary oxygen therapy or noninvasive mechanical ventilation during the trial, the all-cause mortality during the trial, the rate of respiratory failure during the trial it was considered the experimental group is superior to the control group. Log rank test was used to compare the recovery latency between the two groups. For the secondary efficacy indicators/secondary outcomes, T-test or Wilcoxon rank sum test",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "for patients with hypertension and/or diabetes, clinical recovery rate was 51.43% (18/35) in the arbidol group and 54.76% (23/42) in the favipiravir group (P=0.7704), with the difference of recovery rate between two groups (95% CI) was",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Basic characteristics of the participants.",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Table 2. The comparison of clinical recovery rate of day 7 between two group.",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "Comparison of duration of fever, cough relief time and other secondary outcomes between two groups. All rights reserved. No reuse allowed without permission.author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.03.17.20037432Dyspnea after taking medicine, n (%)",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Comparison of antiviral-associated adverse effects between two groups. Fisher's exact test was used for comparison between groups.All rights reserved. No reuse allowed without permission.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}